黑料网

Abstract

Liquid biopsies are emerging as a transformative tool in the diagnosis and management of kidney cancer, offering a non-invasive alternative to traditional tissue biopsies. By analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or exosomes in blood or other body fluids, liquid biopsies provide early detection, real-time monitoring, and personalized treatment strategies. This abstract explores the advantages of liquid biopsies in kidney cancer diagnosis, including their potential for early detection, assessment of disease progression, and tailoring of treatment approaches. Current applications and research highlight the role of liquid biopsies in identifying genetic mutations, assessing tumor heterogeneity, and detecting minimal residual disease (MRD). Despite promising advancements, challenges such as standardization, sensitivity, and integration into clinical practice remain. As research progresses, liquid biopsies are expected to enhance kidney cancer diagnosis and improve patient outcomes.